Therapie mit injizierbaren Fillern beim Lipodystrophiesyndrom

The rapid development of highly active antiretroviral therapy (HAART) has considerably ameliorated the life expectancy of HIV-infected patients. Unfortunately the number of patients under long-term medication with stigmatizing facial lipoatrophy has increased and most affected patients want treatment to remove the facial deformation. During the last years numerous minimally invasive procedures and products have been developed for treatment of facial volume loss due to age or disease. Autologous fat, HA-based volume fillers, synthetic products as poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHa) and even non-degradable substances such as polyacrylamide hydrogel (PAAG) are frequently used for soft tissue augmentation in patients with facial lipoatrophy. The choice of the best product should be made in concordance with the physician’s clinical evaluation and the patient’s preferences. All procedures and products have a significant positive impact on physical and psychological well-being. All procedures require a comprehensive knowledge with respect to materials, injection technique and anatomical structures of the face.